BAXTER INTERNATIONAL INC.

(BAX)
  Report
Delayed Nyse  -  04:00 2022-07-05 pm EDT
65.39 USD   -0.15%
10:49aEvercore ISI Lowers Baxter International's Price Target to $80 From $84, Maintains Outperform Rating
MT
06/27Baxter Details Progress Toward Environmental, Social and Governance (ESG) Priorities in Annual Corporate Responsibility Report
BU
06/24JPMorgan Lowers Price Target for Baxter International to $78 From $90, Maintains Overweight Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/28/2022 06/29/2022 06/30/2022 07/01/2022 07/05/2022 Date
65.25(c) 65.81(c) 64.23(c) 65.49(c) 65.39 Last
2 548 931 2 589 593 3 410 822 2 517 686 1 937 565 Volume
-2.19% +0.86% -2.40% +1.96% -0.15% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 15 751 M - -
Net income 2022 1 563 M - -
Net Debt 2022 14 134 M - -
P/E ratio 2022 21,6x
Yield 2022 1,74%
Sales 2023 16 450 M - -
Net income 2023 2 020 M - -
Net Debt 2023 12 929 M - -
P/E ratio 2023 17,2x
Yield 2023 1,93%
Capitalization 32 976 M 32 976 M -
EV / Sales 2022 2,99x
EV / Sales 2023 2,79x
Nbr of Employees 60 000
Free-Float 73,5%
More Financials
Company
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - kidney dialysis drugs and equipment (30.5%); - systems for delivering medications and intravenous therapy (25.5%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral... 
More about the company
Ratings of Baxter International Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about BAXTER INTERNATIONAL INC.
10:49aEvercore ISI Lowers Baxter International's Price Target to $80 From $84, Maintains Outp..
MT
06/27Baxter Details Progress Toward Environmental, Social and Governance (ESG) Priorities in..
BU
06/24JPMorgan Lowers Price Target for Baxter International to $78 From $90, Maintains Overwe..
MT
06/24Wells Fargo Downgrades Baxter International to Equalweight From Overweight, Adjusts Pri..
MT
06/24BAXTER INTERNATIONAL INC.(NYSE : BAX) added to Russell 1000 Dynamic Index
CI
06/24BAXTER INTERNATIONAL INC.(NYSE : BAX) added to Russell Top 200 Growth Index
CI
06/24BAXTER INTERNATIONAL INC.(NYSE : BAX) added to Russell 1000 Growth Index
CI
06/24BAXTER INTERNATIONAL INC.(NYSE : BAX) added to Russell 1000 Growth-Defensive Index
CI
06/24BAXTER INTERNATIONAL INC.(NYSE : BAX) added to Russell 3000 Growth Index
CI
06/24BAXTER INTERNATIONAL INC.(NYSE : BAX) added to Russell 3000E Growth Index
CI
06/23Food and Drug Administration Says Baxter Recalls Volara System For Risk Of Respiratory ..
MT
06/23FDA Says Baxter International Recalls Volara System For Risk of Respiratory Distress
MT
06/23BAXTER INTERNATIONAL : 2021 SASB Index
PU
06/14TRANSCRIPT : Baxter International Inc. Presents at Goldman Sachs 43rd Annual Global Health..
CI
06/08 Baxter to Host Second-Quarter 2022 Financial Results Conference Call for Investors
BU
More news
News in other languages on BAXTER INTERNATIONAL INC.
06/23Selon la Food and Drug Administration, Baxter rappelle le système Volara pour risque de..
05/25Baxter International publie des prévisions de croissance des ventes à long terme
05/25Baxter fixe une fourchette d'objectifs de croissance des ventes pour 2025
05/25Baxter International Inc. donne ses prévisions de résultats pour l'exercice 2022
05/06Baxter International Inc. annonce des changements au conseil d'administration
More news
Analyst Recommendations on BAXTER INTERNATIONAL INC.
More recommendations
Chart BAXTER INTERNATIONAL INC.
Duration : Period :
Baxter International Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAXTER INTERNATIONAL INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 65,39 $
Average target price 84,62 $
Spread / Average Target 29,4%
EPS Revisions
Managers and Directors
José E. Almeida Chairman, President & Chief Executive Officer
James K. Saccaro Chief Financial Officer & Executive Vice President
Tobi Karchmer Chief Medical Officer & Senior Vice President
Talvis Love Chief Information Officer & Senior Vice President
Paulo Henrique Bolgar Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BAXTER INTERNATIONAL INC.-23.71%32 976
ABBOTT LABORATORIES-21.69%192 989
MEDTRONIC PLC-11.67%121 417
BECTON, DICKINSON AND COMPANY2.45%71 779
HOYA CORPORATION-31.01%31 454
DEXCOM, INC.-42.17%30 470